One-Year Results of Photodynamic Therapy for Small Predominantly Classic Choroidal Neovascular Membranes Secondary to Age-Related Macular Degeneration
Authors:
- 1 July 2007
- journal article
- research article
- Published by SAGE Publications in European Journal of Ophthalmology
- Vol. 17 (5) , 760-767
Abstract
Purpose: To determine the visual and angiographic outcomes of patients with small predominantly classic choroidal neovascular membranes (CNV) undergoing photodynamic therapy (PDT). Methods: The subjects were a cohort of patients with age-related predominantly classic CNV with lesion size of greatest linear diameter of 2000 μm or less treated with PDT Lesion size and visual acuity were recorded at baseline and at 3-month intervals. Visual treatment failure was defined as either loss of at least 15 letters or visual acuity less than 35 letters on a modified Early Treatment Diabetic Retinopathy Study chart. Lesion treatment failure was defined as increase in greatest linear diameter (GLD) of at least 500 μm. Results: Twenty-five eyes of 25 patients were included. Visual treatment failure occurred in 16 and mean visual acuity dropped from 58 letters to 34 letters (p<0.0001). In 11 of these patients this occurred within the first 3 months. Lesion treatment failure occurred in 18 patients. Mean GLD increased from 1331 to 2935 μm (p<0.0001). Early growth of the lesion was associated with poor visual outcome with growth in GLD in the first 3 months of 310 μm in patients without eventual visual treatment failure and 1131 μm in patients with eventual visual failure (p=0.027). Conclusions: Small predominantly classic lesions commonly cause visual deterioration if treated with PDT alone. In the first year over 50% may lose at least 15 letters or drop below 35 letters, with most visual loss occurring in the first 3 months. Visual loss is associated with early lesion growth.Keywords
This publication has 9 references indexed in Scilit:
- TRIPLE THERAPY FOR CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATIONRetina, 2007
- COMBINED PHOTODYNAMIC THERAPY WITH VERTEPORFIN AND INTRAVITREAL BEVACIZUMAB FOR CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATIONRetina, 2006
- Ranibizumab Combined With Verteporfin Photodynamic Therapy in Neovascular Age-Related Macular DegenerationArchives of Ophthalmology (1950), 2006
- Ranibizumab versus Verteporfin for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- Photodynamic Therapy With Verteporfin and Intravitreal Triamcinolone Acetonide in the Treatment of Neovascular Age-related Macular DegenerationAmerican Journal of Ophthalmology, 2006
- Comparison of Early Retreatment with the Standard Regimen in Verteporfin Therapy of Neovascular Age-Related Macular DegenerationOphthalmology, 2005
- Late-onset visual decline following successful treatment of subfoveal choroidal neovascularisation with photodynamic therapyEye, 2005
- Impact of lesion size on photodynamic therapy with verteporfin of predominantly classic lesions in age related macular degenerationBritish Journal of Ophthalmology, 2005
- Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1American Journal of Ophthalmology, 2003